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Introduction
We compared associations of DNA methylation with tumor fea-
tures and clinical variables in n = 99 women with breast can-
cer. Hundreds of hypermethylated genes have been described 
in breast cancer, yet the nature and contribution of these genes 
in their methylated state to overall risk and prognosis is under- 
characterized in non-sporadic breast cancers. The inherent 
heterogeneity of breast cancer and its myriad subtypes pose a 
challenge in any research undertaking. In an effort to limit het-
erogeneity, we narrowed the inclusion criteria for this study to an 
at risk cohort of women with the rationale that distinct epigen-
etic factors common to those with familial breast cancers and/
or known BRCA1 or BRCA2 genetic mutations, are at differing 
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frequencies than in sporadic breast cancers.1-4 Recent studies sug-
gest that specific gene methylation patterns are associated with 
distinct histopathological categories, raising the possibility that 
such patterns may have prognostic value.4-6 This study sought to 
further refine these categories by testing associations of candidate 
gene methylation with tumor features and clinical outcomes such 
as recurrence and metastasis.
How complex epigenetic processes occur, evolve and interact 
with each other at the DNA, RNA and chromatin level are vastly 
complex and not well understood. Although there is debate about 
the nature of these epigenetic phenomena and whether they 
occur in a random or targeted manner,7-11 there is nevertheless 
evidence that global DNA methylation pathways may “overshoot 
their biological targets,”11 and cause some gene methylation to 
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standard statistical correction for such skewed distribution is to 
log transform the data. Accordingly, we log transformed meth-
ylation values for each gene in our study with a zero correction 
factor of log (% M + 1). Because log of zero is undefined, adding 
1 was necessary to obtain finite values.
For each gene in the study, differences in percent methylation 
(as measured by the median log (% M + 1), between these vari-
ables were tested using the Wilcoxon rank sum test (Fig. 1A–J). 
The following variables were excluded from the analysis as none 
of the ten genes were significantly methylated by age (<45, ≥45 
yo), bilateral breast disease (yes, no), BRCA1 or BRCA2 germ-
line mutation status (positive/negative: unknown test results 
and variants of unknown significance were not included in 
the model), or progesterone receptor (PR) status. In summary, 
Figures 1A–J are box plot comparisons of ER, HER2, lymph 
node status, tumor stage and recurrent or metastatic disease vari-
ables by percent methylation for the following ten genes: ERα, 
TWIST, Cyclin D2, CDH1, APC, RASSF1A, HIN1, RARβ, 
BRCA1 and BRCA2, respectively.
Primer selection for quantitative methylation assays. 
QM-MSP was carried out on DNA extracted from formalin 
fixed breast tumors using the primer and probe sequences listed 
in Table 1. Given the phenomenon of field cancerization effects 
reported in histologically “normal” tissues adjacent to tumors, 
and the observation that even microdissected tumors will have 
some percentage of normal cells embedded therein,15,16 these 
primer and probe sets were previously tested in normal breast 
parenchyma derived from healthy women without a breast cancer 
history and showed very low to no methylation.17-19
The classical approach in DNA methylation studies has 
been to consider gene hypermethylation when linked to loss of 
gene expression as a modified version of Knudson’s Two Hit 
Hypothesis.20 However, not all promoter gene methylation is asso-
ciated with silenced or decreased gene expression.21-23 Moreover, 
gene hypermethylation in the absence of changes in expression, 
may nevertheless be useful as a biomarker if consistently found 
to be predictive of clinical outcomes such recurrence, metastasis 
and survival. For example, only two studies have examined the 
relationship between TWIST promoter hypermethylation and 
TWIST RNA and protein, and did not find any alteration in 
gene expression.24,25 Although the limited archival tumor tissues 
in our sample set did not allow gene expression to be assayed 
in tandem with methylation, with the exception of TWIST, 
methylation has consistently been associated with transcriptional 
silencing of the remaining gene loci covered by our primers.24,26-35
Discussion
The main purpose of this study was to explore the predictive con-
tributions of DNA methylation of selected genes, together with 
clinical and tumor features, on breast cancer recurrence and pro-
gression. Of the percent methylation for the ten genes studied in 
occur secondary to upstream effects. Therefore, this may partly 
explain the occurrence of gene hypermethylation in the absence 
of changes in gene expression, but also underscores the potential 
utility of secondarily methylated genes as “surrogate” biomarkers 
when their presence is consistently predictive of specific clinical 
outcomes.
Using quantitative multiplex methylation specific PCR 
(QM-MSP) on a real-time platform, we quantified DNA meth-
ylation for ten genes (APC, RASSF1A, TWIST, ESR1, CDH1, 
Cyclin D2, BRCA1, RARβ, BRCA2 and HIN1), in n = 99 
tumors derived from women with a family history of breast cancer 
with and without deleterious BRCA1 or BRCA2 genetic muta-
tions. The ten genes were chosen because they were either strong 
biological candidate genes for breast carcinogenesis, their known 
or suspected involvement in various aspects of cellular regulation 
and development appears to be suppressed upon methylation, or 
because previous studies showed they were methylated in breast 
tumor cell lines or breast tissues. We report associations of per-
cent methylation for six genes with distinct tumor characteristics 
and clinical outcomes that, depending on their tumor suppressor 
or oncogenic properties, may confer either a protective role or an 
increased risk for recurrence or metastasis.
Results
Frequency distributions of demographic and clinical variables. 
As expected in this cohort, there was an earlier average age of 
breast cancer onset of 44.8 years as compared to the reported 
mean (54 years) and median (61 years) age of onset in the gen-
eral population.12,13 Hormone receptor IHC tumor staining and 
lymph node status of the n = 99 breast cancer cases were similar 
to the general population; slightly over two thirds were estro-
gen/progesterone receptor positive, and approximately two thirds 
were lymph node and HER2 negative at diagnosis (Table 2). 
These tumor type distributions by histology have been shown to 
correlate highly with breast cancer subtypes by gene expression 
profiling.14 Frequency distributions for the remaining variables 
used in the statistical analyses are provided in Table 2. Table 3 
shows the number of tumors of n = 99 total with methylation 
equal to or above the 5% methylation threshold. Additionally, 
the average percent methylation per tumor as well as the range of 
percent methylation values are provided in Table 3.
Associations of percent methylation with clinical variables. 
To examine the contribution of % methylation for each gene to 
a selected set of histological and clinical variables, box plots of 
median percent methylation, based on the log of percent meth-
ylation + 1 or log (% M + 1), were constructed by tumor stage, 
recurrent, metastatic or bilateral breast disease, age at diagno-
sis, BRCA mutation status, and by ER, HER2 and lymph node 
status (Fig. 1A–J). Percent methylation varies widely between 
genes and often has a non-normal distribution, with many values 
skewed toward zero for multiple genes in a particular assay. The 
Figure 1A and B (See opposite page). percent methylation* by eR, heR2, lymph node status, tumor stage and history of recurrent or metastatic dis-
ease. *percent methylation is based on the log of percent methylation + 1 or log (% M + 1). percent eRα (a), TWIsT (B), CyclinD2 (C), CDh1 (D), apC (e), 
RassF1a (F), hIN1 (G), RaRβ (h), BRCa1 (I), BRCa2 (J) methylation by eR, heR2, lymph node status, tumor stage and history of recurrent or metastatic 
disease.
www.landesbioscience.com Cancer Biology & Therapy 855
856 Cancer Biology & Therapy Volume 11 Issue 10
Figure 1C and D (See opposite page). For figure legend, see page 854.
Table 1. DNa primer and probe sequences used in steps 1 + 2 of QM-Msp
Primer Primer Amplimer
Gene abbr. Forward primer (5' à 3') abbr. Reverse primer (3' à 5') size (bp)
apC ext: aaa aCC CTa TaC CCC aCT aC ext: GGT TGT aTT aaT aTa GTT aTa TGT 163
apC FM: aaT aCG aaC Caa aaC GCT CCC RM: TaT GTC GGT TaC GTG CGT TTa TaT 78
apC FU: Taa aTa Caa aCC aaa aCa CTC CC RU: GTT aTa TGT TGG TTa TGT GTG TTT 79
apC Mp: CCC GTC Gaa aaC CCG CCG aTT a Up: TTC CCa TCa aaa aCC CaC Caa TTa aC
BRCa1 ext: TaT TTT GaG aGG TTG TTG TTT aG ext: aaa CaT CaC TTa aaC CCC CTa T 241
BRCa1 FM: TTT CGT GGT aaC GGa aaa GCG RM: CCG TCC aaa aaa TCT Caa CGa a 86
BRCa1 FU: TGG Taa TGG aaa aGT GTG GGa a RU: CCC aTC Caa aaa aTC TCa aCa aa 73
BRCa1 Mp: CTC aCG CCG CGC aaT CGC aaT TT Up: CTC aCa CCa CaC aaT CaC aaT TTT aaT
BRCa2 ext: GTT GGG aTG TTT GaT aaG Gaa T ext: aTC aCa aaT CTa TCC CCT CaC 262
BRCa2 FM: TTT GaT TTT CGG GTG GTG CGT RM: TCa aaa aCT CGC GCC aCa aaC 82
BRCa2 FU: aTT TTT GGG TGG TGT GTG TGT T RU: TCa aaa aCT CaC aCC aCa aaC C 78
BRCa2 Mp: aaC CaC GTa aCG CCG Taa CGC Ga Up: aaC CaC aTa aCa CCa Taa CaC aaC aC
CDh1 ext: Taa TTT TaG GTT aGa GGG TTa T ext: aaC TCa Caa aTa CTT TaC aaT TC 214
CDh1 FM: aGG GTT aTC GCG TTT aTG CGa G RM: aCa aCC aaT Caa Caa CGC Gaa C 82
CDh1 FU: GaG GGT TaT TGT GTT TaT GTG aG RU: CaC aaC Caa TCa aCa aCa Caa aC 84
CDh1 Mp: CCC aaa aCG aaa CTa aCG aCC CGC Up: CTC CCC aaa aCa aaa CTa aCa aCC CaC
CyclinD2 ext: TaT TTT TTG Taa aGa TaG TTT TGa T ext: TaC aaC TTT CTa aaa aaT aaC CC 286
CyclinD2 FM: TTT GaT TTa aGG aTG CGT TaG aGT aCG RM: aCT TTC TCC CTa aaa aCC GaC TaC G 83
CyclinD2 FU: TTa aGG aTG TGT TaG aGT aTG TG RU: aaa CTT TCT CCC Taa aaa CCa aCT aCa aT 78
CyclinD2 Mp: aaT CCG CCa aCa CGa TCG aCC CTa Up: aaT CCa CCa aCa Caa TCa aCC CTa aC
eRα ext: TTG GaG GTT TGG GaG TTT aG ext: aCa aTa aaa CCa TCC Caa aTa C 298
eRα FM: aGG GCG TTC GTT TTG GGa TTG RM: CGC CGa CaC GCG aaC TCT aa 82
eRα FU: TGG TGG aGG GTG TTT GTT TTG RU: aTC CCa CCa aCa CaC aaa CTC 93
eRα Mp: CGa Taa aaC CGa aCa aCC CGa CGa Up: CCC aaT aaa aCC aaa Caa CCC aaC aa
hIN1 ext: GTT TGT Taa GaG Gaa GTT TT ext: CaC CGa aaC aTa Caa aaC aaa aCC aC 286
hIN1 FM: TaG GGa aGG GGG TaC GGG TTT RM: CGC TCa CGa CCG TaC CCT aa 74
hIN1 FU: aaG TTT TTG aGG TTT GGG TaG GGa RU: aCC aaC CTC aCC CaC aCT CCT a 123
hIN1 Mp: aCT TCC TaC TaC GaC CGa CGa aCC Up: Caa CTT CCT aCT aCa aCC aaC aaa CC
RaRβ ext: GTa GGa GGG TTT aTT TTT TGT T ext: aaT TaC aTT TTC Caa aCT TaC TC 239
RaRβ FM: aGa aCG CGa GCG aTT CGa GTa G RM: TaC aaa aaa CCT TCC Gaa TaC GTT 82
RaRβ FU: TTG aGa aTG TGa GTG aTT TGa GTa G RU: TTa Caa aaa aCC TTC Caa aTa CaT TC 83
RaRβ Mp: aTC CTa CCC CGa CGa TaC CCa aaC Up: aaa TCC TaC CCC aaC aaT aCC Caa aC
RassF1a ext: GTT TTa TaG TTT TTG TaT TTa GG ext: aaC TCa aTa aaC TCa aaC TCC C 198
RassF1a FM: GCG TTG aaG TCG GGG TTC RM: CCC GTa CTT CGC Taa CTT Taa aCG 74
RassF1a FU: GGT GTT Gaa GTT GGG GTT TG RU: CCC aTa CTT CaC Taa CTT Taa aC 75
RassF1a Mp: aCa aaC GCG aaC CGa aCG aaa CCa Up: CTa aCa aaC aCa aaC Caa aCa aaa CCa
TWIsT ext: GaG aTG aGa TaT TaT TTa TTG TG ext: CCT CCC aaa CCa TTC aaa aaC 273
TWIsT FM: GTT aGG GTT CGG GGG CGT TGT T RM: CCG TCG CCT TCC TCC GaC Gaa 78
TWIsT FU: GGT TTG GGG GTG TTG TTT GTa TG RU: CCC aCC TCC Taa CCa CCC TCC 104
TWIsT Mp: aaa CGa TTT CCT TCC CCG CCG aaa Up: aaa Caa TTT CCT TCC CCa CCa aaa Ca
QM-Msp, quantitative multiplex-methylation specific pCR. primer abbreviations: ext, external methylation independent primers used in the first step of 
QM-Msp; FM, forward methylated primers; RM, reverse methylated primers; FU, forward unmethylated primers; Mp, methylated probe sequence labeled 
with VIC fluorophore; Up, unmethylated probe sequence labeled with FaM fluorophore.
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tumor tissues, six genes; ERα, TWIST, Cyclin D2, CDH1, APC 
and RASSF1A (Fig. 1A–F) were preferentially methylated for at 
least one of the histopathological variables tested. No significant 
associations were found for the remaining four genes: HIN1, 
RARβ, BRCA1 or BRCA2 (Fig. 1G–J).
Depending on multiple factors including epigenetic regula-
tion, downstream signaling and tissue type, these genes may pos-
sess oncogenic, tumor suppressor properties or both. For example, 
ERα (estrogen receptor alpha, ESR1) is a transcription factor 
that can act as both an oncogene and a tumor suppressor gene 
by its role in modifying expression of a variety of genes in a tis-
sue specific manner as a consequence of the binding of estrogens 
and estrogen receptor modulators.36,37 ERα expression is silenced 
through methylation in a variety of tissues including lung, colon 
and breast and its methylation predicts hormone receptor status 
of breast tissues.6 Therefore, it follows that if the tumorigenic 
functions of ERα are modified via epigenetic pathways, ERα 
methylation would manifest as a protective factor. Supporting 
this hypothesis was our finding that ERα methylation was asso-
ciated with less severe histological features. It was significantly 
more methylated in those breast cancers which did not recur (p 
= 0.03) and trended toward tumors that did not metastasize (p = 
0.06). These results complement the work of Kim et al. (2004) 
who also found ERα methylation was not associated with more 
severe histological indicators such as node positive or high grade 
tumors.38
Similarly, the bHLH transcription factor TWIST is consid-
ered an oncogene due to its role in inhibiting apoptosis, block-
ing expression of other tumor control genes in response to 
DNA damage and promoting epithelial-mesenchymal transi-
tion.39-41 Also supporting the protective hypothesis for oncogene 
Figure 1E and F (See opposite page). For figure legend, see page 854.
Table 2. Frequency distribution of clinical and tumor features for  
N = 99 cases
Breast diagnosis N (%) Percent x 100
CIs 11 11
DCIs-mINV 15 15
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Breast diagnosis: CIs, carcinoma in situ; DCIs-mINV, case diagnosed with 
a <1.0 cm micro-invasive carcinoma, but for which only DCIs remained on 
the tissue block; IC, invasive carcinoma. Lymph node status: indicates if 
lymph nodes were positive or negative for tumor cells at initial diagnosis 
of breast cancer. eR, pR and heR2 status: IhC tumor staining with antibod-
ies to the estrogen and progesterone receptors, and heR2 growth factor 
receptor, respectively. BRCa mutation status: genetic mutation testing of 
BRCa1 and BRCa2 genes; BRCa+, carrier of a known deleterious BRCa1 
or BRCa2 mutation; UNK, test results unknown. By report, the individual 
underwent BRCa mutation testing, but the test result was not reported in 
any of the three Johns hopkins clinical databases abstracted in the study. 
VUs, variant of unknown significance; e.g., a BRCa gene mutation was 
found, but no population data as yet exists to determine if the mutation 
is deleterious; NeG, negative, the patient did not carry a BRCa1 or BRCa2 
gene mutation. NT, not tested.
(continued)
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(p = 0.009), generally considered to have 
a better prognosis than ER-tumors, but 
also with more aggressive HER2+ tumors 
(p = 0.005), suggesting that APC meth-
ylation merits further study as a possible 
marker to identify a subclass of ER+ posi-
tive tumors that behave more aggressively 
and have poorer clinical outcomes.
The tumor suppressor RASSF1A 
(human RAS effector homolog), has 
been found to be epigenetically inacti-
vated in lung, ovary, bladder, kidney and 
breast tumor tissue,53 and is methylated 
in approximately 60–70% of breast can-
cers.34,54 Complementing previous studies 
which show RASSF1A methylation con-
fers a poorer prognosis,55-57 was our find-
ing methylation in 62 of n = 99 tumors 
(Table 3), and significantly higher meth-
ylation with increasing tumor stage from 
TIS to stage III (p = 0.09, p = 0.06 and 
p = 0.01, respectively), with a trend (p = 
0.08) towards HER2+ tumors and in women who were lymph 
node positive at diagnosis (p = 0.006). These findings replicate a 
previous study finding of higher RASSF1A methylation in lymph 
node and HER2+ tumors.46
Methylation of the remaining genes (HIN1, RARb, BRCA1, 
BRCA2), were all negative for associations with clinical and 
tumor features. Negative findings for the tumor suppressor 
genes BRCA1 and BRCA2 were not surprising given the char-
acteristically low frequencies of BRCA2 tumor methylation in 
our study (Table 3) and others.58,59 Moreover, data have shown 
lower percent BRCA1 methylation or varied methylation levels 
of other candidate genes in women with BRCA germline genetic 
mutations,3,60 as well as varied gene methylation levels in famil-
ial breast “BRCAx” cancers negative for deleterious BRCA1 or 
BRCA2 genetic mutations.1,61
Both tumor heterogeneity and varied methylation findings 
in BRCAx or familial breast cancers have been previously docu-
mented.1,62-64 Indeed, even in our familial breast cancer cohort, 
there was heterogeneity by tumor type, age of onset and BRCA 
mutation status. For example, the majority of women (56%), had 
not been tested for heritable mutations in the BRCA1 or BRCA2 
genes. Of the women that were tested, 22% were negative for a 
BRCA1 or BRCA2 genetic mutation, 12% were either BRCA1 or 
BRCA2 positive, 5% had a mutation or variant of unknown sig-
nificance (VUS) and 5% were tested, but their BRCA test result 
was not reported in any of the three clinical databases abstracted 
for this study (Table 2). Also, 30% of the women with a con-
firmed deleterious BRCA genetic mutation did not have a strong 
family history, but rather only had either one first or second 
degree relative with breast cancer (data not shown).
This retrospective study was conducted using archival breast 
tumors and medical records abstraction dating from 1986–2004. 
methylation, was our finding that TWIST was preferentially 
methylated in lymph node negative tumors (p = 0.06), and in 
breast cancer cases which did not metastasize (p = 0.006), with a 
trend (p = 0.1) towards very low to no methylation in high grade 
stage III tumors. Likewise, Cyclin D2 (CCND2), is most often 
considered an oncogene that acts as a crucial cell cycle regula-
tor involved in cell growth and malignant processes.42-44 Several 
previous studies have shown Cyclin D2 to be methylated in inva-
sive breast carcinoma,42-44 and we found Cyclin D2 methylation 
was associated (p = 0.03) with non-metastatic breast cancers. As 
with the other genes in our set with the exception of TWIST, 
hypermethylation of Cyclin D2 has consistently been linked to 
decreased expression.
Because CDH1 (E-cadherin), mediates normal cell to cell 
adhesion in epithelial cells,45 its loss of expression, either though 
epigenetic or other mechanisms, has been associated with more 
severe clinical outcomes such as lymph node invasion and metas-
tasis.46-48 Interestingly, neither this study nor a study of sporadic 
breast cancer,49 found CDH1 methylation in association with 
lymph node metastases. Although we found CDH1 methyla-
tion was associated with HER2+ (p = 0.03) tumors, only two 
tumors in this cohort had methylation values that exceeded the 
5% threshold (Table 3) and therefore this result must be viewed 
with caution.
As opposed to oncogene methylation, we found methylation of 
the tumor suppressor genes, APC and RASSF1A, was associated 
with more prognostically severe clinical outcomes. For example, 
the tumor suppressor APC (adenomatous polyposis coli), can be 
lost through genetic and epigenetic mechanisms, but in breast 
cancer, methylation frequency increases with tumor stage and 
size, and has been associated with a poor prognosis.50-52 Likewise, 
we found APC methylation was associated with ER+ tumors 
Figure 1G and H (See opposite page). For figure legend, see page 854.
Table 3. Methylation in n = 99 Breast tumors exceeding 5.0%  methylation threshold
No. of tumors
Average  percent (% 
x100)
Range of  percent (% 
x100)
Gene name Methylated* Tumor Methylation Tumor Methylation
eRα 26 32 6–84
TWIsT 37 38 6–93
Cyclin D2 24 44 7–93
CDh1 2 19 17–21
apC 44 41 8–91
RassF1a 62 38 6–96
hIN1 28 62 5–95
RaRb 40 37 6–93
BRCa1 23 47 7–84
BRCa2 7 33 7–89
Numer of tumors methylated: Total number of tumors that exceeded a methylation threshold of 
5.0 percent for each of ten genes. Range of percent tumor methylation and percent tumor meth-
ylation: Range of percent methylation and mean methylation values, respectively for those genes 
that exceeded a 5.0% methylation threshold.
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who provided the breast cancer diagnosis, tumor type and grade. 
During slide review, the percentage of tumor epithelium relative 
to stroma/adjacent histologically normal tissue was estimated, 
with values of tumor epithelium achieving as much as 85% per 
sample. Once the presence of tumor was confirmed by H&E, a 
5 μm section was cut from each tumor block and used for DNA 
extraction. Due to the unavoidable and variable admixture of 
each tumor with adjacent histologically “normal” epithelium and 
stroma, we previously assayed methylation in normal breast tis-
sues as a comparison, and found very low to no methylation for 
the 10 loci in this study.17-19
DNA extraction from tumors, cell lines and human sperm. 
FFPE sections were de-paraffinized in xylene for 20 minutes, 
scraped from the slide and extracted in 30 μl TNES (10 mM 
Tris, pH 8.0, 150 mM NaCl, 2 mM EDTA, 0.5% SDS) con-
taining 40 μg of proteinase K for 5 h at 52°C. After Proteinase 
K treatment, cells were heat inactivated at 99°C for 10 min and 
centrifuged at 16,000x g for 10 min. 13.5 of the 30 μl super-
natant was used directly as a source of DNA for sodium bisul-
fite (NaBi) treatment, performed according to Fackler et al. 
(2004).56 NaBi treatment converts non-methylated cytosine 
residues to uracil (later replicated as thymidine during PCR), 
whereas methylated cytosines remain unchanged. Such con-
version of the original sequence allows distinct primer sets to 
be made that are specific to unmethylated and methylated CG 
sequences respectively for each sample. DNA was extracted from 
cell lines with phenol-chloroform,66 and from human semen 
using the PUREGENE DNA Purification Kit (Gentra Systems, 
Minneapolis, MN), according to the manufacturer’s instruc-
tions and stored at -20°C.
Positive and negative methylation controls. Breast carci-
noma cell line MDA-MB231 was obtained from American Type 
Culture Collection (www.atcc.org, Manassas, VA) and cultured 
as directed. Human sperm was obtained from a healthy volun-
teer. Many genes are highly methylated in MDA-MB231 cells 
and therefore this cell line is used as a positive methylation con-
trol both before and after treatment with a DNA methyltransfer-
ase. Human sperm DNA (HSD) has been shown to have a lower 
degree of genomic methylation as compared to other somatic 
cells,67 and has therefore been used as a negative, unmethylated 
reference control in methylation studies of tumor control genes.68 
HSD treated with SssI methyltransferase (New England Biolabs 
Inc., Beverly, MA) was also used as 100% methylation positive 
control for the 10 candidate genes assayed in this study. Positive 
methylation controls: 2 μg of either MDA-MB231 or HSD was 
incubated with S-adenosyl-L-methionine and 1 unit of SssI meth-
yltransferase (New England Biolabs, Beverly, MA) for 1.5 h at 
37°C according to manufacturers instructions prior to sodium 
bisulfite treatment.
Quantitative multiplex—methylation specific polymerase 
chain reaction. Quantitative methylation analysis was performed 
on sodium bisulfite treated tumor DNAs and controls with the 
QM-MSP real-time method using “protocol C” as described in 
Swift-Scanlan et al. (2006).19 Both methylated and unmethylated 
The amount of missing data (Table 2) for HER2 IHC status 
reflects those tumors that were archived prior to the discovery, 
development or common use of the HER2 antibody in clinical 
pathology practice. Therefore, both negative and positive find-
ings for associations between gene methylation and HER status 
must be considered in this context. Due to the finite amount 
of nucleic acids obtained from limited archival specimens, we 
were not able to perform gene expression profiling in tandem 
with methylation analyses to determine intrinsic (e.g., luminal 
A, luminal B, HER2-enriched, basal-like and normal-like),65 
breast cancer subtypes. However, the study strengths include our 
selection of a non-sporadic breast cancer cohort and the highly 
quantitative QM-MSP method that allowed us to detect and set 
thresholds for low levels of methylation that might otherwise test 
differently on qualitative gel-based approaches.
In summary, although our methods include the classical 
approach of considering gene hypermethylation linked to loss of 
gene expression, we also support the merits of evaluating hyper-
methylated biomarkers in the context of purported oncogene or 
tumor suppressor function, regardless of their effects on gene 
expression. Also, the parsing of analyses by consideration of 
oncogene or tumor suppressor function, allows the exploration 
of a protective or risk factor role when analyzed in the context 
of important clinical outcomes such as recurrence or metastasis.
Taken as a whole, these findings illustrate the existence of 
specific patterns of gene methylation in association with distinct 
combinations of histopathological features. Such results empha-
size the potential utility of characterizing methylation patterns in 
order to better define breast tumors such as the luminal, HER2, 
normal like and basal like subtypes characterized by gene expres-
sion profiling. Future studies of DNA methylation and breast 
cancer will assay gene expression in tandem with other clinical 
correlates and outcomes.
Materials and Methods
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